Join to View Full Profile
ArrayBiopharmaCambridge, MA 02140
Dr. Sandor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
McGill University Faculty of MedicineClass of 1990
Certifications & Licensure
VA State Medical License 2000 - 2026
Publications & Presentations
PubMed
- 25 citationsA Phase Ib/II Study of the BRAF Inhibitor Encorafenib plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid TumorsRyan J. Sullivan, Jeffrey S. Weber, Sapna Pradyuman Patel, Reinhard Dummer, Matteo S. Carlino
Clinical Cancer Research. 2020-07-15 - 469 citationsEncorafenib, Binimetinib, and Cetuximab inV600E-Mutated Colorectal Cancer.Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai
The New England Journal of Medicine. 2019-10-24 - 158 citationsBinimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEA...Eric Van Cutsem, Sanne Huijberts, Axel Grothey, Rona Yaeger, Pieter Jan Cuyle
Journal of Clinical Oncology. 2019-03-20
Press Mentions
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsAugust 18th, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of DirectorsApril 27th, 2020
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of DirectorsApril 27th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
